1. Everson GT, Cooper C, Hézode C, et al. High SVR rates with 12 to 24 weeks of ritonavir-boosted danoprevir plus Peg-IFNα-2a (40KD)/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study. Hepatology. 2012;56(4 Suppl):552A.
2. Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. J Hepatol. 2011;55(5):972–9.
3. Reddy MB, Chen Y, Haznedar JO, et al. Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug–drug interaction study. Clin Pharmacokinet. 2012;51(7):457–65.
4. Goelzer P, Morcos PN, Tran J, et al. Coadministration of ritonavir with the HCV protease inhibitor danoprevir substantially reduces reactive metabolite formation both in vitro and in vivo. Hepatology. 2012;56(4 Suppl):580A.
5. Eley T, Han Y-H, Huang S-P, et al. In vivo and in vitro assessment of asunaprevir as an inhibitor and substrate of OATP transporters in healthy volunteers. Rev Antivir Ther Infect Dis. 2012;6:7.